NK/T cell lymphoma, nasal type
Conditions
Interventions
IMED-P/GDP-P:Receive sequential IMED-P/GDP-P chemotherapy for 6 cycles
IMED-P:Receive 6 cycles IMED-P chemotherapy
GDP-P:Receive 6 cycles GDP-P chemotherapy
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Aged 18-80 years; pathology confirmed extranodal NK/T cell lymphoma,nasal type; with measurable lymphoma lesions;Arbor stage I-II; Previously untreated; Adequate hematologic parameters and liver and kidney functions; ECOG 0-3;Estimated time of survival more than 3 months; Women of childbearing age with a negative pregnancy test; Give signed informed consent before enrollment.
Exclusion criteria
Exclusion criteria: Participated in other clinical trials in the last 3 months; Secondary or transforming lymphoma;Arbor stage III-IV; Previous malignancies; NEUT<1.0×10^9/L or HGB<80g/L or PLT<90×109/L; Active infection; Decompensated heart failure, dilated cardiomyopathy, an electrocardiogram showing ST segment depression and myocardial infarction in the last 6 months; Functional insufficiency of vital organs; clinical symptoms of brain dysfunction, severe mental illness; pregnant or lactating women; With history of other malignant tumors; With other serious diseases that conflict with this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5-year overall survial; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;complete remission rate;5-year progression-free survival;safety; | — |
Countries
China
Contacts
Public ContactTongyu LIN
Sun Yat-sen University Cancer Center
Outcome results
None listed